MedTrace Logo

Cytosponge™ for Post-Chemoradiation Surveillance of Oesophageal Cancer

NCT03529669 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 41

Last updated 2022-07-25

Study results available
· View outcomes & findings →

Summary

This is a feasibility study testing the use of the Cytosponge™ device in patients with known oesophageal cancer treated with pre-operative or definitive chemoradiation. All participants will receive one Cytosponge™ procedure at one time-point within 4-16 weeks after completion of chemoradiotherapy.

Conditions

  • Oesophageal Cancer

Interventions

DEVICE

Cytosponge™

Cytosponge™ is a capsule-sized device which contains an expandable, spherical mesh which is attached to a string. The capsule dissolves in the stomach after swallowing, releasing the sponge which is then retrieved by gently pulling the string after five minutes. As the sponge is pulled out it collects the cells from the lining of the gullet.

Sponsors & Collaborators

  • Centre for Statistics in Medicine

    collaborator OTHER

  • Cancer Research UK

    collaborator OTHER

  • University of Cambridge

    collaborator OTHER

  • Cambridge University Hospitals NHS Foundation Trust

    collaborator OTHER

  • University of Oxford

    lead OTHER

Principal Investigators

  • Prof Somnath Mukherjee · University of Oxford

Study Design

Allocation
NA
Purpose
DEVICE_FEASIBILITY
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-04-18
Primary Completion
2020-01-30
Completion
2020-01-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03529669 on ClinicalTrials.gov